Unlock instant, AI-driven research and patent intelligence for your innovation.

Pyrazole boric acid compound, pharmaceutical composition containing pyrazole boric acid compound, and application of pyrazole boric acid compound and pharmaceutical composition

A compound and pharmaceutical technology, applied in the field of medicine, can solve the problems of poor in vitro and in vivo stability, large toxic and side effects, and poor biological selectivity.

Active Publication Date: 2022-02-22
北京嵩润医药科技有限责任公司
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing proteasome inhibitors have disadvantages such as poor bioselectivity, poor stability in vivo and in vitro, poor inhibitory effect on solid tumors, and high toxicity and side effects, which limit their clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrazole boric acid compound, pharmaceutical composition containing pyrazole boric acid compound, and application of pyrazole boric acid compound and pharmaceutical composition
  • Pyrazole boric acid compound, pharmaceutical composition containing pyrazole boric acid compound, and application of pyrazole boric acid compound and pharmaceutical composition
  • Pyrazole boric acid compound, pharmaceutical composition containing pyrazole boric acid compound, and application of pyrazole boric acid compound and pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0093] Next, the present application will be described in detail through examples, but the present application is not limited to these examples. Unless otherwise stated, all reagents, materials, and equipment used in the following examples are commercially available; and all reagents are commercially available chemically or analytically pure.

[0094] Route 1: Synthesis of Compound 1-Compound 26

[0095]

preparation example 1

[0096] Preparation Example 1: Synthesis of Compound 1

[0097] Step 1: Synthesis of Intermediate 1-2

[0098] To a solution of KOH (16.8 g, 300 mmol) in 95% EtOH (125 mL) was added 1-(2-hydroxyphenyl)ethan-1-one (13.6 g, 100 mmol) and benzaldehyde (10.6 g, 100 mmol) ). The solution was stirred at room temperature for 12 hours until complete as monitored by TLC, poured into ice water (1000 mL) and acidified to pH 2-3 with 4N HCl. After standing, the precipitate was filtered and washed with water until the pH value reached 6-7, and dried in vacuum to obtain a crude yellow solid (23.1 g, yield 95.1%).

[0099] Step 2: Synthesis of Intermediates 1-3

[0100] The crude product from step 1 (8.69 g, 40 mmol) and ethyl hydrazinoacetate hydrochloride (7.74 g, 48 mmol) were suspended in EtOH (150 mL). The solution was heated to reflux for 12 h, then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (100 mL) and water (100 mL), then acidified to pH 5-6 ...

preparation example 2- preparation example 26

[0111] Preparation Example 2-Preparation Example 26: According to route 1, using the same steps as the synthesis of compound 1, compound 2-compound 26 was obtained as a white solid, and the compounds are shown in the following table:

[0112]

[0113]

[0114]

[0115]

[0116]

[0117]

[0118] Route 2: Synthesis of compound 27

[0119]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
clearance rateaaaaaaaaaa
Login to View More

Abstract

The invention relates to a pyrazole boric acid compound as shown in a formula I, pharmaceutically acceptable salts or stereoisomers of the pyrazole boric acid compound, pharmaceutical compositions containing the pyrazole boric acid compound or the pharmaceutically acceptable salts or stereoisomers of the pyrazole boric acid compound, and application of the pyrazole boric acid compound, the pharmaceutically acceptable salts or stereoisomers and the compositions. The compound, the pharmaceutically acceptable salts or stereoisomers thereof and the pharmaceutical composition containing the compound or the pharmaceutically acceptable salts or stereoisomers can be used for preparing a proteasome inhibitor.

Description

technical field [0001] The application belongs to the field of medicine, specifically, it relates to pyrazole boronic acid compounds shown in formula I, their pharmaceutically acceptable salts or their stereoisomers and pharmaceutical compositions containing them, and relates to their preparation of proteasome Use in inhibitors. Background technique [0002] As the main site for the hydrolysis of intracellular proteins, the proteasome plays an important role in cell cycle regulation, cellular stress response and immune response. Therefore, the proteasome has become an ideal target for the treatment of various diseases, including tumors, malaria parasites, asthma, etc. [0003] There are currently several proteasome inhibitors on the market, such as bortezomib, MLN9708 (trade name Ninlaro; 31), carfilzomib, and NPI0052 (trade name Marizomib), etc. However, existing proteasome inhibitors have disadvantages such as poor bioselectivity, poor in vivo and in vitro stability, poo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07F5/02A61P35/00A61P11/06A61P25/28A61P33/06A61K31/69
CPCC07F5/025A61P35/00A61P11/06A61P25/28A61P33/06Y02A50/30A61K31/69
Inventor 李润涛王元强韩利强宋转转葛泽梅王欣
Owner 北京嵩润医药科技有限责任公司